Abstract

Dectin-1 (gene Clec7a), a receptor for β-glucans, plays important roles in the host defense against fungi and immune homeostasis of the intestine. Although this molecule is also suggested to be involved in the regulation of tumorigenesis, the role in intestinal tumor development remains to be elucidated. In this study, we find that azoxymethane-dextran-sodium-sulfate-induced and ApcMin-induced intestinal tumorigenesis are suppressed in Clec7a−/− mice independently from commensal microbiota. Dectin-1 is preferentially expressed on myeloid-derived suppressor cells (MDSCs). In the Clec7a−/− mouse colon, the proportion of MDSCs and MDSC-derived prostaglandin E2 (PGE2) levels are reduced, while the expression of IL-22 binding protein (IL-22BP; gene Il22ra2) is upregulated. Dectin-1 signaling induces PGE2-synthesizing enzymes and PGE2 suppresses Il22ra2 expression in vitro and in vivo. Administration of short chain β-glucan laminarin, an antagonist of Dectin-1, suppresses the development of mouse colorectal tumors. Furthermore, in patients with colorectal cancer (CRC), the expression of CLEC7A is also observed in MDSCs and correlated with the death rate and tumor severity. Dectin-1 signaling upregulates PGE2-synthesizing enzyme expression and PGE2 suppresses IL22RA2 expression in human CRC-infiltrating cells. These observations indicate a role of the Dectin-1-PGE2-IL-22BP axis in regulating intestinal tumorigenesis, suggesting Dectin-1 as a potential target for CRC therapy.

The effect of β-glucans and their receptor Dectin-1 in tumor development remains controversial. Here the authors show that Dectin-1 signaling promotes the development of colorectal cancer (CRC) by inducing prostaglandin E2 production in myeloid-derived suppressor cells and by suppressing IL-22BP expression, suggesting dectin-1 blockade as a potential therapeutic target for CRC.

Details

Title
Blocking Dectin-1 prevents colorectal tumorigenesis by suppressing prostaglandin E2 production in myeloid-derived suppressor cells and enhancing IL-22 binding protein expression
Author
Tang, Ce 1   VIAFID ORCID Logo  ; Sun, Haiyang 2 ; Kadoki, Motohiko 3 ; Han, Wei 3 ; Ye, Xiaoqi 4 ; Makusheva, Yulia 3 ; Deng, Jianping 5 ; Feng, Bingbing 5 ; Qiu, Ding 5 ; Tan, Ying 5 ; Wang, Xinying 5 ; Guo, Zehao 6 ; Huang, Chanyan 7 ; Peng, Sui 8 ; Chen, Minhu 6 ; Adachi, Yoshiyuki 9 ; Ohno, Naohito 9 ; Trombetta, Sergio 10 ; Iwakura, Yoichiro 3   VIAFID ORCID Logo 

 Sun Yat-sen University, No.58, Zhong Shan Er Lu, Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Sun Yat-sen University, Institute of Precision Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Tokyo University of Science, Center for Animal Disease Models, Research Institute for Biomedical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861) 
 Sun Yat-sen University, Institute of Precision Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Tokyo University of Science, Center for Animal Disease Models, Research Institute for Biomedical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861) 
 Tokyo University of Science, Center for Animal Disease Models, Research Institute for Biomedical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861) 
 Sun Yat-sen University, No.58, Zhong Shan Er Lu, Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Tokyo University of Science, Center for Animal Disease Models, Research Institute for Biomedical Sciences, Chiba, Japan (GRID:grid.143643.7) (ISNI:0000 0001 0660 6861) 
 Sun Yat-sen University, Institute of Precision Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X) 
 Sun Yat-sen University, No.58, Zhong Shan Er Lu, Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X) 
 Sun Yat-sen University, Department of Anesthesiology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X) 
 Sun Yat-sen University, No.58, Zhong Shan Er Lu, Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); Sun Yat-sen University, Institute of Precision Medicine, The First Affiliated Hospital, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X) 
 Tokyo University of Pharmacy and Life Sciences, Hachioji, Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo, Japan (GRID:grid.410785.f) (ISNI:0000 0001 0659 6325) 
10  Boehringer Ingelheim USA, Ridgefield, USA (GRID:grid.418412.a) (ISNI:0000 0001 1312 9717) 
Pages
1493
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2787776935
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.